Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines.

about

Peptide-Based Treatment: A Promising Cancer Therapy The combined treatment with novel platinum(II) complex and anti-MUC1 increases apoptotic response in MDA-MB-231 breast cancer cells.Immunotherapy for breast cancer: past, present, and future.

P2860

Q26777032-E8514997-D52D-439A-A6E9-B5ECD8ABAFDF Q36621615-39D418CA-7B63-4081-B45B-FAB6F0B09CB8 Q38787696-293DEE0D-0F54-4C9A-8B08-B5A008075A20

P2860

Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines.

Item

http://www.wikidata.org/entity/Q38215394

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines.

@en

type

Item

label

Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines.

@en

prefLabel

Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines.

@en

P1476

Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines

@en

P2093

Mojgan Allahyari

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

The blockade of immune checkpoints in cancer immunotherapy

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

Breast cancer vaccines: a clinical reality or fairy tale?

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

P304

927-961

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/1744666X.2014.916211

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Elham Mohit

Atieh Hashemi

P577

2014-05-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24867051

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines.

about

P2860

P2860

Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921